Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation

Exclusion Criteria

• •1. Small vessel: mean reference size \< 2.3 mm by QCA(quantitative coronary angiography)
• •2. True bifurcation lesion with a large side branch (reference vessel diameter \> 2.3mm) requiring a complex two-stent approach
• •3. Left main lesions
• •4. Ostial lesions within 3mm of the origin: right coronary artery, left anterior descending artery, or left circumflex artery
• •5. Impaired delivery of the Absorb BVS is expected:
• •Extreme angulation (≥90°) proximal to or within the target lesion.
• •Excessive tortuosity (≥two 45° angles) proximal to or within the target lesion.
• •Moderate or heavy calcification proximal to or within the target lesion. 6. In-stent restenotic lesions
• •ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (with 12- 24 hour after symptoms onset)
• •Prior percutaneous coronary intervention within the target vessel during the last 12 months.
• •Prior percutaneous coronary intervention within the non-target vessel or any peripheral intervention is acceptable if performed anytime \>30 days before the index procedure, or between 24 hours and 30 days before the index procedure if successful and uncomplicated.
• •Left ventricular ejection fraction (LVEF) \< 30%
• •Hypersensitivity or contraindication to device material and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.
• •Persistent thrombocytopenia (platelet count \<100,000/µl)
• •Any history of hemorrhagic stroke or intracranial hemorrhage, transient ischemic attack (TIA) or ischemic stroke within the past 6 months
• •A known intolerance to a study drug (aspirin, clopidogrel or ticagrelor)
• •Patients requiring long-term oral anticoagulants or cilostazol
• •Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure.
• •A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.
• •Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
• •Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).
• •Life expectancy \< 5 years for any non-cardiac or cardiac causes
• •Unwillingness or inability to comply with the procedures described in this protocol.
• •Patient's pregnant or breast-feeding or child-bearing potential.